Biotechnology, Healthcare, and Innovation by Halozyme

  • Ezequiel Gomes
  • 18.06.2026
Halozyme Therapeutics stock under bearish pressure with technicals pointing to likely short-term consolidation
Halozyme Therapeutics announced that David Kang and Chris Wahl will participate in #CRS2026 events.They will take part in a workshop on Advancing Technologies & Strategies for SC Drug Delivery on ...
  • Ezequiel Gomes
  • 29.03.2026
Record revenue and royalties fail to lift Halozyme Therapeutics stock amid sustained technical weakness
Halozyme Therapeutics reported record full-year 2025 results as revenue rose 38 percent to $1.4 billion. Royalties increased 52 percent to $868 million.Growth was driven by ENHANZE, partner ...
  • Artem Shendetskii
  • 19.11.2025
Halozyme Therapeutics expands portfolio with Elektrofi acquisition
Halozyme Therapeutics has successfully completed its acquisition of Elektrofi, broadening its drug delivery capabilities. By incorporating Elektrofi's Hypercon ultra-high concentration ...